GLP-1 medicines and sudden vision loss: what regulators and studies say about NAION

What NAION is

NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain terms, the optic nerve at the back of one eye gets too little blood and is damaged. It usually causes sudden, painless vision loss in one eye. A 2026 review describes it as typically sudden, painless and irreversible. It happens to people who have never taken a GLP-1 medicine.

Background rates help put the studies in context. In the Danish and Norwegian national registries, people with type 2 diabetes who started a different diabetes medicine (an SGLT2 inhibitor) developed NAION at 1.18 cases per 10,000 person-years in Denmark and 0.92 in Norway. A person-year is one person followed for one year.

Who is at higher risk, whatever medicine they take

Reviews name a small cup-to-disc ratio as the most robust anatomical predictor. That means a crowded optic nerve head, sometimes called a disc at risk, which a person is born with. Diabetes, high blood pressure, high cholesterol, sleep apnea and advanced kidney disease are also linked to higher susceptibility. Australia's regulator says people with a disc at risk have the highest risk with semaglutide.

What regulators decided

Regulators in Europe, the U.K. and Australia have acted. The U.S. FDA has not changed the labels the Atlas read.

A regulator listing a side effect means the evidence was judged enough to warn about. It does not mean the cause is proven. Label text changes, so check the current label.

What the studies found

Nearly all the research is on semaglutide and in people with type 2 diabetes. The studies were built differently and point in different directions, which is why the table shows them one by one.

What the numbers mean in plain terms

Three ideas help read these studies. First, NAION is rare in anyone, so even a doubling of risk means a small number of extra cases. The Danish and Norwegian study estimated about 1.4 extra cases per 10,000 people per year, close to the regulators' figure of one extra case per 10,000 person-years.

Second, the studies look at different people, mostly with type 2 diabetes, and compare against different medicines, which is one reason their results point in different ways.

Third, none of them can show cause. Observational studies cannot fully separate the effect of the medicine from the effect of the diabetes, blood vessel disease or sleep apnea that led to the prescription.

Tirzepatide, higher doses and the pills

For tirzepatide the Atlas found reports in the FDA database with a smaller signal than semaglutide's, a published case report of NAION in a woman four weeks after starting, and Australian advisers who did not find the evidence supported a signal. A 2026 review said that semaglutide 7.2 mg (the Wegovy HD strength) and the pill orforglipron (Foundayo) warrant monitoring for eye effects, while noting that direct evidence of NAION risk with either is not available.

Sudden vision changes: what regulators say

The EMA, the U.K.'s MHRA and Australia's TGA give the same safety message: sudden loss of vision, including partial loss, or vision that worsens quickly, needs urgent medical attention. The EMA and MHRA add that semaglutide should be stopped if NAION is confirmed. That decision belongs to the clinician who confirms it.

One 2026 review suggests that checking for crowded optic disc anatomy and asking about any past NAION may be worth considering before treatment starts. That is the review authors' suggestion. No U.S. label the Atlas read mentions an eye exam for NAION.

A different condition: diabetic retinopathy

Diabetic retinopathy is damage to the retina from high blood sugar over time. The Wegovy, Zepbound and Mounjaro labels each warn that rapid improvement in blood sugar control has been associated with a temporary worsening of diabetic retinopathy, and that people with a history of it should be monitored. A 2026 review found worsening more closely tied to the size of the drop in HbA1c than to a class-specific effect on the retina.

Quick answers

Can Ozempic or Wegovy cause blindness?

Regulators in Europe, the U.K. and Australia list NAION, a sudden loss of vision in one eye, as a very rare or rare side effect of semaglutide, and the loss can be permanent. Whether the medicine causes it is still debated: the studies point in different directions, and the Danish and Norwegian study estimated about 1.4 extra cases per 10,000 people per year.

Do U.S. labels warn about NAION?

Not in the versions the Atlas read. The Wegovy (6/2026), Zepbound (8/2026) and Mounjaro (8/2026) labels do not name NAION or optic neuropathy. They do warn about diabetic retinopathy complications in people with type 2 diabetes.

How common is NAION?

In the Danish and Norwegian registries, 0.92 to 1.18 cases per 10,000 person-years among people with type 2 diabetes who started an SGLT2 inhibitor, and 2.19 to 2.90 among those who started semaglutide.

Is tirzepatide linked to NAION?

The evidence is thinner. Reports to the FDA database show a smaller signal than for semaglutide, and a 2026 review called findings for tirzepatide absent, inconsistent or weaker. Australia added NAION to the tirzepatide product information as a post-marketing adverse effect, using class wording.

Who is most at risk of NAION?

Reviews point to a crowded optic disc (a small cup-to-disc ratio) as the best-established risk factor, with diabetes, high blood pressure, high cholesterol, sleep apnea and advanced kidney disease also linked to higher susceptibility.

What are the warning signs?

Regulators describe sudden vision loss, including partial loss, or vision that worsens quickly in one or both eyes. Their advice is to seek urgent medical attention.

Do I need an eye exam before starting?

No U.S. label the Atlas read requires one for NAION. One 2026 review suggests checking for crowded optic disc anatomy may be worth considering. Ask your prescriber and an eye doctor.

Does stopping the medicine help?

The EMA and MHRA say semaglutide should be stopped if NAION is confirmed. The Atlas found no study showing that stopping restores vision.

Questions to ask

• Do I have a crowded optic disc or other eye risk factors, and should an eye doctor take a look?
• Have I ever had NAION in either eye?
• Do my diabetes, blood pressure, cholesterol or sleep apnea change the picture?
• What vision changes should make me call right away, and who do I call after hours?
• If my vision changes suddenly, who should I see first, and how fast?

What is still unknown

• Whether GLP-1 medicines cause NAION. Every study the Atlas found is observational, reviews call the link a safety signal, and the studies disagree on direction.
• The size of any added risk in people without diabetes. Most large studies are in type 2 diabetes.
• Whether tirzepatide, the pills and higher doses carry the same risk as semaglutide. Reviews describe the evidence as absent, inconsistent, weaker or not yet available.
• Why the military health-records study found lower odds in type 2 diabetes while others found higher odds.
• Whether the FDA will add NAION to U.S. labels. The Atlas found no FDA statement on it.
• Label text and regulator pages change. The versions here were read in October 2026.